Anti Inflammatory News and Research

RSS

Obama administration turns bright spotlight on prescription painkiller abuse

The Obama administration turned a bright spotlight on prescription painkiller abuse in April when the Office of National Drug Control Policy released a national action plan and a statement from Vice President Joe Biden.

2 Jul 2011

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

30 Jun 2011

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc. a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases today announced the initiation of the SYNERGY trial, a Phase 2b clinical trial evaluating Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

29 Jun 2011

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Anacor Pharmaceuticals, the Drugs for Neglected Diseases initiative (DNDi), and SCYNEXIS Inc. today announced the successful completion of pre-clinical studies for the first new oral drug candidate discovered specifically to combat human African trypanosomiasis (HAT), also known as sleeping sickness.

29 Jun 2011

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, today announced that it has renegotiated the terms of its commercial partnership with Meda for Xerese, its unique marketed product for cold sores (herpes labialis).

29 Jun 2011

FDA clears Nuvo's IND for Lidocaine Spray formulation

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products for the topical treatment of pain, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application filed May 27, 2011 for a novel topical Lidocaine Spray formulation (NRI-ANA), allowing for initiation of Phase 1 studies.

29 Jun 2011

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Anacor Pharmaceuticals announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis.

28 Jun 2011

Cardium to purchase Transdel's business assets

Cardium Therapeutics today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel (TDLP-110), which is a topically-administered analgesic for the treatment of musculoskeletal pain.

27 Jun 2011

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

BioLineRx, a biopharmaceutical drug development company, and Yissum Research Development Company Ltd., the Technology Transfer Company of the Hebrew University of Jerusalem, announced today that they have signed a worldwide, exclusive license agreement for BioLineRx to develop and commercialize BL-7040, an orally available Phase II ready molecule for treating Inflammatory Bowel Disease (IBD) and other inflammatory diseases.

27 Jun 2011

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

27 Jun 2011

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

New Phase 2 clinical trial data published online today in The New England Journal of Medicine show that patients with moderate to severe chronic kidney disease and type 2 diabetes receiving bardoxolone methyl for 52 weeks experienced a sustained improvement in kidney function throughout the treatment period, as measured by estimated glomerular filtration rate.

27 Jun 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

An essential aspect of oral surgery is controlling the patient's pain following a procedure. The goal is to relieve pain and promote a rapid recovery, without opioid side effects. An initial study shows that Dyloject, a new intravenous form of the drug diclofenac, has promise for achieving these goals.

27 Jun 2011

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

A new anti-inflammatory drug used by patients with type 2 diabetes improved their kidney function during a year-long study involving researchers from UT Southwestern Medical Center.

24 Jun 2011

Bodies resist weight loss efforts when food intake is reduced drastically

If you've been trying to lose weight and suspect your body's working against you, you may be right, according to a University of Illinois study published in Obesity.

24 Jun 2011

HDL in CAD patients different from HDL in healthy individuals

High levels of "good" cholesterol (HDL cholesterol) are associated with a decreased risk of coronary artery disease (CAD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke. This suggests that therapeutics that increase HDL levels could be clinically useful.

24 Jun 2011

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Idera Pharmaceuticals, Inc. announced today the presentation of IMO-3100 mechanism of action data in a preclinical model of arthritis.

24 Jun 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Allergan, Inc. today announced a new study published in the peer-reviewed journal Surgery for Obesity and Related Diseases that found the cost of a gastric banding weight-loss surgery procedure, such as Allergan's LAP-BAND Adjustable Gastric Banding System, was offset by reductions in obesity-related medical costs within 2.25 years for surgery eligible patients with diabetes, and within four years of the procedure for all surgery eligible patients.

23 Jun 2011

Cyanotech fourth quarter revenues increase to $5,218,000

Cyanotech Corporation, a world leader in microalgae-based, high-value nutrition and health products, today announced financial results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

23 Jun 2011

Resveratrol may make old age more tolerable, but not prevent it

A University of Florida review of research finds the polyphenol compound known as resveratrol found in red wine, grapes and other fruits may not prevent old age, but it might make it more tolerable.

23 Jun 2011

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

A neurological scientist at Rush University Medical Center has received a grant from the National Institutes of Health (NIH) to evaluate whether cinnamon, a common food spice and flavoring material, may stop the destructive process of multiple sclerosis.

23 Jun 2011

Anti Inflammatory News and Research

Obama administration turns bright spotlight on prescription painkiller abuse

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Zalicus commences Synavive SYNERGY Phase 2b clinical trial for rheumatoid arthritis

Anacor, DNDi and SCYNEXIS complete SCYX-7158 pre-clinical studies for combating sleeping sickness

Medivir, Meda renegotiate agreement for cold sores medicine, Xerese

FDA clears Nuvo's IND for Lidocaine Spray formulation

Positive preliminary results from Anacor's AN2728 Phase 2b trial on psoriasis

Cardium to purchase Transdel's business assets

Yissum, BioLineRx sign license deal to develop and commercialize BL-7040 for IBD

New anti-inflammatory drug improves kidney function in patients with type 2 diabetes

New bardoxolone methyl Phase 2 trial data on kidney disease, diabetes presented at ERA-EDTA 2011

Intravenous diclofenac holds promise against severe pain following oral surgery

New drug improves kidney function for patients with type 2 diabetes and chronic kidney disease

Bodies resist weight loss efforts when food intake is reduced drastically

HDL in CAD patients different from HDL in healthy individuals

Idera presents IMO-3100 data on preclinical model of arthritis at FOCIS 2011

Reductions in obesity-related medical costs offset cost of gastric banding surgery within 2.25 years

Cyanotech fourth quarter revenues increase to $5,218,000

Resveratrol may make old age more tolerable, but not prevent it

Rush scientist receives NIH grant to evaluate whether cinnamon may treat MS

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News